6gg4 Citations

An allostatic mechanism for M2 pyruvate kinase as an amino-acid sensor.

OpenAccess logo Biochem J 475 1821-1837 (2018)
Related entries: 6gg3, 6gg5, 6gg6

Cited: 32 times
EuropePMC logo PMID: 29748232

Abstract

We have tested the effect of all 20 proteinogenic amino acids on the activity of the M2 isoenzyme of pyruvate kinase (M2PYK) and show that, within physiologically relevant concentrations, phenylalanine, alanine, tryptophan, methionine, valine, and proline act as inhibitors, while histidine and serine act as activators. Size exclusion chromatography has been used to show that all amino acids, whether activators or inhibitors, stabilise the tetrameric form of M2PYK. In the absence of amino-acid ligands an apparent tetramer-monomer dissociation Kd is estimated to be ∼0.9 µM with a slow dissociation rate (t1/2 15 min). X-ray structures of M2PYK complexes with alanine, phenylalanine, and tryptophan show the M2PYK locked in an inactive T-state conformation, while activators lock the M2PYK tetramer in the active R-state conformation. Amino-acid binding in the allosteric pocket triggers rigid body rotations (11°) stabilising either T or R states. The opposing inhibitory and activating effects of the non-essential amino acids serine and alanine suggest that M2PYK could act as a rapid-response nutrient sensor to rebalance cellular metabolism. This competition at a single allosteric site between activators and inhibitors provides a novel regulatory mechanism by which M2PYK activity is finely tuned by the relative (but not absolute) concentrations of activator and inhibitor amino acids. Such 'allostatic' regulation may be important in metabolic reprogramming and influencing cell fate.

Articles - 6gg4 mentioned but not cited (6)

  1. An allostatic mechanism for M2 pyruvate kinase as an amino-acid sensor. Yuan M, McNae IW, Chen Y, Blackburn EA, Wear MA, Michels PAM, Fothergill-Gilmore LA, Hupp T, Walkinshaw MD. Biochem J 475 1821-1837 (2018)
  2. Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation. Macpherson JA, Theisen A, Masino L, Fets L, Driscoll PC, Encheva V, Snijders AP, Martin SR, Kleinjung J, Barran PE, Fraternali F, Anastasiou D. Elife 8 e45068 (2019)
  3. Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2. Nandi S, Dey M. J Biol Chem 295 5390-5403 (2020)
  4. Distinctive regulatory properties of pyruvate kinase 1 from Aedes aegypti mosquitoes. Petchampai N, Murillo-Solano C, Isoe J, Pizarro JC, Scaraffia PY. Insect Biochem Mol Biol 104 82-90 (2019)
  5. Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase. Battisti UM, Gao C, Akladios F, Kim W, Yang H, Bayram C, Bolat I, Kiliclioglu M, Yuksel N, Tozlu OO, Zhang C, Sebhaoui J, Iqbal S, Shoaie S, Hacimuftuoglu A, Yildirim S, Turkez H, Uhlen M, Boren J, Mardinoglu A, Grøtli M. Nutrients 15 577 (2023)
  6. Serendipitous Identification of a Covalent Activator of Liver Pyruvate Kinase. Battisti UM, Gao C, Nilsson O, Akladios F, Lulla A, Bogucka A, Nain-Perez A, Håversen L, Kim W, Boren J, Hyvönen M, Uhlen M, Mardinoglu A, Grøtli M. Chembiochem 24 e202200339 (2023)


Reviews citing this publication (7)

  1. Pyruvate kinase M2: A simple molecule with complex functions. Alquraishi M, Puckett DL, Alani DS, Humidat AS, Frankel VD, Donohoe DR, Whelan J, Bettaieb A. Free Radic Biol Med 143 176-192 (2019)
  2. Metabolic reprogramming results in abnormal glycolysis in gastric cancer: a review. Liu Y, Zhang Z, Wang J, Chen C, Tang X, Zhu J, Liu J. Onco Targets Ther 12 1195-1204 (2019)
  3. A critical review of the role of M2PYK in the Warburg effect. Harris RA, Fenton AW. Biochim Biophys Acta Rev Cancer 1871 225-239 (2019)
  4. The molecular mechanisms of LncRNA-correlated PKM2 in cancer metabolism. Tao T, Wu S, Sun Z, Ma W, Zhou S, Deng J, Su Q, Peng M, Xu G, Yang X. Biosci Rep 39 BSR20192453 (2019)
  5. From Glucose to Lactate and Transiting Intermediates Through Mitochondria, Bypassing Pyruvate Kinase: Considerations for Cells Exhibiting Dimeric PKM2 or Otherwise Inhibited Kinase Activity. Chinopoulos C. Front Physiol 11 543564 (2020)
  6. Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents. Rathod B, Chak S, Patel S, Shard A. RSC Med Chem 12 1121-1141 (2021)
  7. The role of PKM2 in cancer progression and its structural and biological basis. Wu B, Liang Z, Lan H, Teng X, Wang C. J Physiol Biochem 80 261-275 (2024)

Articles citing this publication (19)